Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $122.2 million.

  • Ironwood Pharmaceuticals' Non-Current Assets fell 42.05% to $122.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.2 million, marking a year-over-year decrease of 42.05%. This contributed to the annual value of $168.5 million for FY2024, which is 29.12% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Non-Current Assets stood at $122.2 million, which was down 19.16% from $151.2 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Non-Current Assets ranged from a high of $386.9 million in Q2 2021 and a low of $61.1 million during Q1 2021.
  • For the 3-year period, Ironwood Pharmaceuticals' Non-Current Assets averaged around $213.7 million, with its median value being $217.4 million (2024).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Non-Current Assets soared by 550.77% in 2021, and later tumbled by 42.05% in 2025.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Non-Current Assets stood at $381.7 million in 2021, then decreased by 16.19% to $319.9 million in 2022, then declined by 25.67% to $237.8 million in 2023, then dropped by 29.12% to $168.5 million in 2024, then tumbled by 42.05% to $122.2 million in 2025.
  • Its Non-Current Assets was $122.2 million in Q3 2025, compared to $151.2 million in Q2 2025 and $166.6 million in Q1 2025.